VTGN
What one share of Vistagen Therapeutics holds
Pharmaceutical Preparations
We are a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia.
Vistagen Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$1.66 |
| Cash and investments | $0.38 |
| Debt | $0.00 |
| Book value | $0.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $54.65 | −$497.11 | — | −$145.18 | — | −$183.03 |
| 2013 | $5.77 | −$12.00 | — | −$99.71 | — | −$361.51 |
| 2014 | — | −$114.28 | — | −$58.02 | — | −$301.74 |
| 2015 | — | −$318.26 | — | −$62.99 | — | −$386.52 |
| 2016 | $0.00 | −$872.52 | $0.45 | −$82.04 | — | — |
| 2017 | $4.98 | −$46.30 | $0.95 | −$29.88 | — | $1.99 |
| 2018 | $0.00 | −$33.64 | $0.00 | −$19.57 | — | $9.01 |
| 2019 | — | −$27.02 | $0.18 | −$15.44 | — | $4.98 |
| 2020 | $0.00 | −$15.07 | $0.00 | −$10.78 | — | −$3.08 |
| 2021 | $0.38 | −$14.74 | $0.10 | −$4.30 | — | — |
| 2022 | $0.17 | −$7.38 | $0.03 | −$6.89 | — | $9.40 |
| 2023 | −$0.03 | −$8.51 | $0.08 | −$7.22 | — | $1.53 |
| 2024 | $0.06 | −$1.52 | $0.00 | −$1.33 | — | $4.23 |
| 2025 | $0.02 | −$1.67 | — | −$1.36 | — | $2.41 |
| 2026 | $0.03 | −$1.83 | — | −$1.74 | — | $0.87 |